NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer … – NEC Global

Tokyo, April 8, 2024 - NEC Corporation (NEC; TSE: 6701) has released a white paper, "Towards the realization of AI drug development: Comprehensive process workflow for the commercial use of personalized cancer vaccines". This white paper introduces (1) a comprehensive process workflow that can be applied to a wide range of processes, starting from tumor sample collection to vaccine design, manufacturing, supply, and administration, (2) important perspectives for consideration in the workflow, and (3) advanced technologies that will contribute to the realization of the workflow.

NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

Read this article:

NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer ... - NEC Global

Related Posts
Tags: